S2 Genomics
S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications.
- Company typePrivate
- Founded2016
- HeadquartersLivermore, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What S2 Genomics does
S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications. It enables automated processing of raw tissues into single cells or nuclei for genomics and cell biology studies. The company's vision is to provide products that process raw tissues into samples ready for genomic analyses. S2 Genomics was founded in 2016 and is headquartered in Livermore, CA.
S2 Genomics firmographics
Firmographics- Name
- S2 Genomics
- Legal name
- S2 Genomics, Inc.
- Website
- https://s2genomics.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications.
- Ownership category
- akta.pro rank
S2 Genomics industry classification
Industry- Product category
- Laboratory Instruments for Single-Cell Genomics
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where S2 Genomics is headquartered
LocationHeadquarters
- HQ city
- Livermore
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
S2 Genomics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Instruments and Consumables: S2 Genomics generated revenue through the sale of Singulator tissue dissociation instruments along with associated consumables and reagents for single-cell sample preparation
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
S2 Genomics product offering
Product offeringCore offering
S2 Genomics develops and manufactures the Singulator platform, an automated tissue dissociation system that converts solid tissue samples (fresh, frozen, and FFPE) into sequencing-ready single-cell or nuclei suspensions for downstream single-cell genomics research. The company also offers complementary Coulter-principle cell counting instruments (Moxi line) and fluorescence phenotyping systems used as upstream quality control for sequencing workflows.
Product overview
Precision Cell Systems (formerly S2 Genomics) offers an integrated portfolio of precision instruments for cell-based workflows serving single-cell genomics research. The product line centers on the Singulator platform (Singulator 100, 200, 200+) for automated tissue dissociation, which converts fresh, frozen, and FFPE tissues into sequencing-ready single cells or nuclei suspensions. Complementary instruments include the Moxi line (Moxi V, Moxi Z, Moxi GO II) for Coulter-principle cell counting and fluorescence analysis, providing upstream precision for downstream sequencers and cytometers. The Velocyt instrument rounds out the portfolio for cell analysis applications. These instruments address specific workflow bottlenecks including tissue dissociation, cell counting, and quality control steps that traditionally introduce variance in single-cell genomics.
Differentiator
Problem solved
Functional benefit
Products and services
- Singulator 100 Automated tissue dissociation instrument for processing fresh and frozen tissues into single-cell or nuclei suspensions for single-cell genomics; validated for 2 mg minimum input with enzyme-free protocols.
- Singulator 200 Enhanced automated tissue dissociation system with expanded tissue type support including FFPE processing capability, delivering software-locked reproducibility across sites for standardized single-cell sample preparation.
- Singulator 200+ System Flagship automated tissue dissociation system featuring fully automated FFPE-to-nuclei processing without xylene. Processes tissue samples in 40–60 minutes with more than 1 million nuclei yield from a single 50 µm FFPE curl, eliminating toxic solvents and manual ethanol series through GREEN cartridge technology.
- Moxi V Volumetric Coulter-principle cell counter offering less than 2% CV precision with 8-second results. Features zero maintenance cassette-based design with volumetric debris exclusion and supports nuclei counting protocols.
- Moxi Z Enhanced Coulter-principle cell counter with expanded dynamic range for counting and sizing cells from 5–60 µm. Used for PBMC analysis, WBC counting, and proliferation assays with NIST-traceable precision.
- Moxi GO II Combined Coulter-principle counting and two-color fluorescence cell counter/analyzer. Features 488nm laser with dual PMTs for viability, GFP, apoptosis, and immunophenotyping assays, with native 21 CFR Part 11 compliance for regulated environments. Results in under 10 seconds with FCS 3.1 export and FlowJo compatibility.
- Velocyt Cell analysis instrument for fluorescence phenotyping and cell counting workflows within the company's single-cell analysis portfolio.
Quantifiable outcome
- 10x more viable cells recovered vs. gentleMACS in peer-reviewed glioblastoma study with 96% viability
Companies that use S2 Genomics
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
S2 Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration12 records
Feature2 records
S2 Genomics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Precision Cell SystemsmajorS2 Genomics was acquired by Precision Cell Systems in September 2025 as part of a consolidation strategy. The acquisition combined S2 Genomics with ORFLO to create a company serving over 700 customers with more than 1,000 instruments.
Scale indicators2 records
Recent moves5 records
Expansion highlights6 records
S2 Genomics competitors and assessment
Company assessmentDirect peers
- Miltenyi Biotec: Miltenyi Biotec's gentleMACS is the dominant automated tissue dissociation platform that the Singulator directly competes against and is benchmarked against (10x more viable cells recovered in a published glioblastoma study).
- NanoString Technologies: NanoString is a spatial transcriptomics platform mentioned as adjacent/competing in S2 Genomics' market context and overlaps in FFPE-based spatial workflows targeted by the Singulator 200+.
- Akoya Biosciences: Akoya is a spatial phenomics platform explicitly cited as a spatial genomics competitor in S2 Genomics' market context; both companies compete for spatial and single-cell research budgets from translational and immuno-oncology labs.
- Vizgen: Vizgen's MERSCOPE spatial transcriptomics platform is explicitly called out as a downstream integration and competing technology in S2 Genomics' market context, serving FFPE and fresh tissue spatial workflows.
Broad incumbents
- 10x Genomics: 10x Genomics is the leading single-cell and spatial genomics platform whose Chromium, Xenium, and Visium instruments are validated downstream of the Singulator; serves overlapping customers with a much broader portfolio spanning sequencing kits to instruments.
- Bio-Rad Laboratories: Bio-Rad is a broad life sciences instrument and consumables supplier (including ddPCR and cell sorting) that competes for similar cell-biology and genomics research budgets and serves many of the same core facilities.
- Beckman Coulter Life Sciences: Beckman Coulter (a Danaher company) provides flow cytometry, cell counting, and lab automation products that overlap with the Moxi line and compete for cell analysis workflow spend in research and bioprocessing.
- Becton Dickinson (BD): BD Biosciences offers flow cytometry, cell sorting, and single-cell genomics sample prep instruments that overlap with both the dissociation and cell-counting workflows addressed by S2 Genomics' Singulator and Moxi platforms.
Emerging players
- Parse Biosciences: Parse Biosciences offers single-cell sequencing solutions (Evercode) and is a validated downstream integration partner for Singulator-prepared samples, competing more broadly for single-cell research spend.
- Mission Bio: Mission Bio's Tapestri single-cell multi-omics platform is a validated Singulator downstream integration, serving overlapping oncology and translational research customers with a different downstream modality.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
S2 Genomics social profiles
Digital presenceS2 Genomics compliance and trust
Trust signalCompliance3 records
S2 Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
S2 Genomics leadership team
Management profileNumber of profiles
Profiles2 records
S2 Genomics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
S2 Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about S2 Genomics
What does S2 Genomics do?
S2 Genomics develops and manufactures the Singulator platform, an automated tissue dissociation system that converts solid tissue samples (fresh, frozen, and FFPE) into sequencing-ready single-cell or nuclei suspensions for downstream single-cell genomics research. The company also offers complementary Coulter-principle cell counting instruments (Moxi line) and fluorescence phenotyping systems used as upstream quality control for sequencing workflows.
Is S2 Genomics a public or private company?
S2 Genomics is a private company. It is classified as venture growth investor backed and is currently acquired.
When was S2 Genomics founded?
S2 Genomics was founded in 2016. It employs 11 to 50 people.
Where is S2 Genomics based?
S2 Genomics is headquartered in Livermore, United States, in the North America region.
How does S2 Genomics make money?
One revenue line is on record: instruments and Consumables.
Who are S2 Genomics's main competitors?
Direct peers on record are Miltenyi Biotec, NanoString Technologies, Akoya Biosciences and Vizgen. Broad incumbents are 10x Genomics, Bio-Rad Laboratories, Beckman Coulter Life Sciences and Becton Dickinson (BD). Emerging players are Parse Biosciences and Mission Bio.
Does S2 Genomics have an API?
No public API is recorded for S2 Genomics.
What industry is S2 Genomics in?
S2 Genomics's product category is Laboratory Instruments for Single-Cell Genomics. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 334516 and its SIC code is 3826.